Official Release

Hansoh Pharmaceutical Group Company Limited ("Hansoh Pharma" or the "Company") has received approval from the National Medical Products Administration (NMPA) to market its new Class 1 drug Hengmu (Tenofovir Amibufenamide Tablets), for the treatment of chronic Hepatitis B in adult patients. Hengmu is the fifth Class 1 innovative drug independently developed by Hansoh Pharma.&n🀅bsp;

Hengmu is a new second-generation tenofovir independently developed by Hansoh Pharma, and also the first oral anti-hepatitis B virus (HBV) drug originally developed in China. Tenofovir Amibufenamide Tablets are a novel nucleotide reverse transcriptase inhibitor with an optimized structure that provides higher cell membrane penetration and easier access to hepatocytes for hepatic targeting, while effectively improving drug plasma stability and reducing systemic TFV exposure for safer long-term treatment. Clinical study results showed that:Compared with tenofovir disoproxil fumarate (Viread, TDF), Hengmu requires less than one-tenth the dose to achieve similar antiviral efficacyAntiviral efficacy comparable to that of first-line drugs Less impact on bone density and kidney, with better bone and kidney safety  According to the data, China is still "a country with high hepatitis B virus infections", specifically: about 70 million cases of chronic hepatitis B virus infections, including about 20-30 million cases of chronic hepatitis B patients; there is still a long way to go in terms of prevention and treatment. The approval of Hengmu for marketing will provide new treatment options with low dose, high efficacy and safety for clinical practices, bring new therapeutic regimens with long-term medication and better compliance for adult patients with chronic hepatitis B, and improve their quality of life and well-being. Hansoh Pharma will continue to uphold the corporate mission to "create excellence in pharmaceuticals, enhance innovation in China", pursue innovation-driven development, and develop more high-quality and high-efficacy innovative drugs, so as to improve the health and quality of life of human beings, assist Chinese medicine in the transition from "made in China" to "created in China", and extend the benefits of Chinese original new drugs to patients worldwide.